Clinical data
AHFS/ International Drug Names
MedlinePlus a682619
  • US: B (No risk in non-human studies)
Routes of
ATC code R06AX18 (WHO)
Legal status
Legal status
Pharmacokinetic data
Biological half-life 1.5 hours
Excretion Renal
CAS Number 87848-99-5 N
PubChem (CID) 5284514
ChemSpider 4447574 YesY
KEGG D02760 YesY
Chemical and physical data
Formula C22H24N2O2
Molar mass 348.438 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking histamine H1 receptors.

This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories. It should not be confused with Benadryl Once a Day which has cetirizine as the active ingredient and is also sold by McNeil in the UK. It is available as an over-the-counter medicine in the UK, and is available with or without pseudoephedrine under the Benadryl brand.

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D also contains the decongestant pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

Comparisons with other popular antihistamines

Unlike cetirizine or loratadine, for which the standard dose is one tablet per day, a single acrivastine tablet may be taken up to three times a day.[2] It is not to be taken by over 65s, pregnant women, or people with compromised liver or kidney function.


  1. SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
  2. "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.